reports
AC Immune to Present at the Jefferies 2025 London Healthcare Conferenc...
AC Immune to Present at the Jefferies 2025 London Healthcare Conference AC Immune to Present at the Jefferies 2025 London Healthcare Conference Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. The fireside chat will take place on November 18, 2025, at 4:30 ...
AC Immune Reports Third Quarter 2025 Financial Results and Provides a ...
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn Cash resources of CHF 108.5 million as of September 30, 2025, provide funding to the end of Q3 2027 excluding any income from potential milestonesPeer-reviewed papers covering groundbreaking results including clinical data on ACI-35.030 (JNJ-64042056) publish...
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of ...
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalitiesIncludes immunotherapies and small molecule drugs targeting intracellular proteinopathiesLeadership in groundbreaking early-stage clinical trials reinforces Company’s competencies Lausanne, Switzerland, October 28, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage bi...
First Characterization of a TDP-43 PET Tracer Published in Nature Comm...
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of neurodegenerative diseases including ALS, FTD and LATE, and a co-pathology in Alzheimer’s and Parkinson’s diseasesPET imaging of aggregated TDP-43 could facilitate precision medicine in these diseases, whose shared clinical features complicate differentia...
AC Immune Sa: 1 director
A director at AC Immune Sa sold 45,000 shares at 3.130USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immun...
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential antibody response in individuals with early Alzheimer’s diseaseACI-35.030, developed using AC Immune’s SupraAntigen® technology, generated rapid, potent polycl...
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extend...
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30%Increased emphasis on late-stage clinical development of active immunotherapy portfolio for Alzheimer’s and Parkinson’s diseases and progressing high value candidates enabling intracellular targetingNear term clinical milestones remain unchangedCash resources of CHF 127.1 million a...
AC Immune Reports Second Quarter 2025 Financial Results and Provides a...
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical developmentACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025Third Alzheimer’s disease cohort (AD3) in the Phase 2...
AC Immune Reports First Quarter 2025 Financial Results and Provides a ...
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson’s disease (PD)Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025Presentations at Inter...
AC Immune Reports Further Positive Interim Results from Phase 2 Trial ...
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizationsRepeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titersACI-7104.056 is well tol...
AC Immune Announces Upcoming Presentations and Industry Symposium on A...
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseasesMultiple presentations at the International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2025) showcasing the diversity of the company’s precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC...
AC Immune Reports Full Year 2024 Financial Results and Provides a Corp...
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercializationACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer’s disease (AD) and DS expected in 2025Enrollment progress in JNJ-20...
AC Immune to Participate in Upcoming Investor Conferences
AC Immune to Participate in Upcoming Investor Conferences AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in the following investor conferences in March: Leerink Partners 2025 Global Healthcare Conference,Management will participate in investor meetings on March 10, 2025Barclays 27th Annual Global Healthcare Conference,Management will participate ...
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of A...
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drugNo cases of amyloid-related imaging abnormalities observed in this study populationBased upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndrome Lausanne, Switzerland, December 10, 2024 – AC Immune SA (NASDAQ...
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7...
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations100% of patients receiving ACI-7104.056 responded against the target antigenACI-7104.056 is well tolerated with no clinically relevant safety issues reported to date Lausanne, Switzerland, Novem...
AC Immune to Present at the Jefferies 2024 London Healthcare Conferenc...
AC Immune to Present at the Jefferies 2024 London Healthcare Conference AC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 London Healthcare Conference, taking place in-person in London on November 19-21, 2024. The fireside chat will take place on November 20, 2...
AC Immune Reports Third Quarter 2024 Financial Results and Provides a ...
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and immunogenicity dataPrescreening rate for Phase 2b Retain trial of JNJ-2056 (ACI-35.030) in Alzheimer’s disease (AD) triggered CHF 24.6 million milestone under agreementJNJ-2056 received Fast Track designation from the U.S. FDACash of CHF 157.9 million at the end of September, plus the CHF 24.6 million milestone payment r...
AC Immune Receives Second Milestone Payment Following Progress in Phas...
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in SeptemberPotentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic ADFDA Fast Track designation granted in July for ACI-35.030 (now “JNJ-2056”) for AD Lausanne, Switzerland...
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track ...
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMIThis Fast Track designation applies across Alzheimer’s disease, progressive supranuclear palsy, and corticobasal degenerationFollows two previous Fast Track designations for ACI-35.030 and ACI-24.060 active immunotherapiesAffirms AC Immune’s leadership and commitment to b...
AC Immune Reports Second Quarter 2024 Financial Results and Provides a...
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront and total potential milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial in Alzheimer’s disease (AD) on track with enrolment expectationsACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson’s disease (PD) on track for safety and immunogenicity interim data...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.